株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ミトコンドリア病:パイプラインの分析

Mitochondrial Diseases - Pipeline Review, H1 2014

発行 Global Markets Direct 商品コード 293893
出版日 ページ情報 英文 50 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
ミトコンドリア病:パイプラインの分析 Mitochondrial Diseases - Pipeline Review, H1 2014
出版日: 2014年05月30日 ページ情報: 英文 50 Pages
概要

ミトコンドリア病とは、赤血球以外のすべての細胞に存在するミトコンドリアの異常によるもので、mtDNAまたはnDNAの遺伝性変異もしくは自然突然変異によって通常ミトコンドリアに存在するたんぱく質またはRNA分子の機能低下を引き起こすものです。発育遅延、痴呆、脱力感、痙攣、過敏性腸症候群、筋痛、下痢、便秘などの症状があります。

当レポートでは、世界におけるミトコンドリア病治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および彼らが開発中の製品のレビューなどをお届けします。

イントロダクション

  • 調査範囲

ミトコンドリア病の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

ミトコンドリア病:開発中の治療薬:企業別

ミトコンドリア病:開発中の治療薬:大学・研究機関別

ミトコンドリア病:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

ミトコンドリア病:開発中の製品:企業別

ミトコンドリア病:開発中の製品:大学・研究機関別

ミトコンドリア病:治療薬開発に従事している企業

  • NeuroVive Pharmaceutical AB
  • Edison Pharmaceuticals, Inc.
  • ElexoPharm GmbH

ミトコンドリア病:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • バチキノン
  • OT-15
  • MTP-131
  • NVP-015
  • Alkylaminoquinoneベースの多機能性ラジカルクエンチャー
  • Eurostars Program
  • ミトコンドリア病向け薬剤
  • 細胞エネルギー代謝を標的とした薬剤
  • ミトコンドリア病向け小分子
    • 製品概要
    • 作用機序
    • R&Dの進捗

ミトコンドリア病:最近のパイプライン動向

ミトコンドリア病:休止中のプロジェクト

ミトコンドリア病:中止プロジェクト

ミトコンドリア病:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC5051IDB

Global Markets Direct's, 'Mitochondrial Diseases - Pipeline Review, H1 2014', provides an overview of the Mitochondrial Diseases's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mitochondrial Diseases, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mitochondrial Diseases and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Mitochondrial Diseases
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Mitochondrial Diseases and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Mitochondrial Diseases products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Mitochondrial Diseases pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Mitochondrial Diseases
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Mitochondrial Diseases pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Mitochondrial Diseases Overview
  • Therapeutics Development
    • Pipeline Products for Mitochondrial Diseases - Overview
    • Pipeline Products for Mitochondrial Diseases - Comparative Analysis
  • Mitochondrial Diseases - Therapeutics under Development by Companies
  • Mitochondrial Diseases - Therapeutics under Investigation by Universities/Institutes
  • Mitochondrial Diseases - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Mitochondrial Diseases - Products under Development by Companies
  • Mitochondrial Diseases - Products under Investigation by Universities/Institutes
  • Mitochondrial Diseases - Companies Involved in Therapeutics Development
    • NeuroVive Pharmaceutical AB
    • Edison Pharmaceuticals, Inc.
    • ElexoPharm GmbH
  • Mitochondrial Diseases - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • vatiquinone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OT-15 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MTP-131 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NVP-015 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Alkylaminoquinone Based Multifunctional Radical Quenchers - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Eurostars Program - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug for Mitochondrial Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs Targeting Cellular Energy Metabolism - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Mitochondrial Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Mitochondrial Diseases - Recent Pipeline Updates
  • Mitochondrial Diseases - Dormant Projects
  • Mitochondrial Diseases - Discontinued Products
  • Mitochondrial Diseases - Product Development Milestones
    • Featured News & Press Releases
      • Mar 18, 2013: St George's University Of London Receives £3.3m MRC Grant For Developing New Treatment For Rare Metabolic Disorder
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Mitochondrial Diseases, H1 2014
  • Number of Products under Development for Mitochondrial Diseases - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Investigation by Universities/Institutes, H1 2014
  • Mitochondrial Diseases - Pipeline by NeuroVive Pharmaceutical AB, H1 2014
  • Mitochondrial Diseases - Pipeline by Edison Pharmaceuticals, Inc., H1 2014
  • Mitochondrial Diseases - Pipeline by ElexoPharm GmbH, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Mitochondrial Diseases Therapeutics - Recent Pipeline Updates, H1 2014
  • Mitochondrial Diseases - Dormant Projects, H1 2014
  • Mitochondrial Diseases - Discontinued Products, H1 2014

List of Figures

  • Number of Products under Development for Mitochondrial Diseases, H1 2014
  • Number of Products under Development for Mitochondrial Diseases - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top